Welcome to our dedicated page for Lifeward Ltd. Ordinary Shares news (Ticker: LFWD), a resource for investors and traders seeking the latest updates and insights on Lifeward Ltd. Ordinary Shares stock.
Lifeward™, formerly known as ReWalk Robotics Ltd, is a pioneering medical device company dedicated to transforming the lives of individuals with physical limitations and disabilities. Founded in 2001, Lifeward designs, develops, and commercializes innovative solutions that span the continuum of care in physical rehabilitation and recovery. The company's mission is to relentlessly drive innovation, delivering functional and health benefits in clinical settings as well as in the home and community.
Headquartered in the United States, with additional operations in Israel and Germany, Lifeward's product portfolio includes the ReWalk Personal Exoskeleton, ReWalk Rehabilitation Exoskeleton, AlterG Anti-Gravity systems, ReStore Exo-Suit, and MyoCycle FES systems. These devices empower individuals to achieve their goals through improved mobility and health outcomes.
Lifeward has garnered significant recognition for its life-changing technology, particularly the ReWalk Exoskeleton, which has been crucial for individuals with spinal cord injuries. The company's efforts have been acknowledged by the Centers for Medicare & Medicaid Services (CMS), which has made strides in establishing a reimbursement pathway for the ReWalk Personal Exoskeleton. This development is a significant step toward making this revolutionary technology accessible to more people.
In recent news, Lifeward has unveiled its new branding and expanded its portfolio with the inclusion of AlterG Anti-Gravity systems. The rebranding reflects the company's broader vision and commitment to elevating the standard of care for individuals facing physical limitations. CEO Larry Jasinski stated that the transformation to Lifeward symbolizes their goal to be the driving force in overcoming physical disabilities.
Lifeward operates through markets in the United States and Europe, with additional sales in Asia, the Middle East, and South America. The company's financial health remains robust, as evidenced by their latest financial results and continuous efforts to innovate and expand their market presence. Lifeward's commitment to excellence is further highlighted by partnerships with healthcare providers and legislative efforts to enhance access to their technologies for veterans and other individuals in need.
For more information about Lifeward's mission and product offerings, visit GoLifeward.com.
Lifeward (Nasdaq: LFWD), a global leader in rehabilitation and recovery solutions, has announced its participation in the upcoming ThinkEquity Conference. Chief Financial Officer Mike Lawless will deliver a company overview presentation on October 30, 2024, at 3:00 PM EDT. The presentation will be accessible through the company's Investor Relations website and via webcast. Lawless will also conduct one-on-one meetings with investors during the conference. A replay of the presentation will remain available for 90 days after the event.
Lifeward (Nasdaq: LFWD) has announced the launch of direct sales for its AlterG product line in Germany, effective immediately. This strategic move, announced at the REHACARE 2024 conference in Düsseldorf, adds AlterG products to the company's German sales portfolio alongside the ReWalk Personal Exoskeleton.
The company expects several financial benefits from this direct sales approach, including increased revenue due to a more focused sales effort and higher margins with minimal additional investment. Lifeward aims to leverage its existing sales and support infrastructure in Germany to expand market penetration and accelerate its path to profitability both in Germany and globally.
While Lifeward begins direct sales, PHYSIOMED GROUP will continue to provide service and support to its existing base of nearly 500 customers in Germany and distribute AlterG units in parallel with the Lifeward team.
ReWalk Robotics has officially changed its name to Lifeward , completing the rebranding initiative announced on January 29, 2024. The change follows shareholder approval on September 4, 2024, and approval from the Israel Companies Registrar on September 10, 2024. This transformation reflects the company's expanded mission to elevate care standards for overcoming physical limitations and disabilities.
CEO Larry Jasinski stated that the rebranding aligns with Lifeward's goal to empower individuals to pursue their passions despite physical challenges. The company's U.S. and German subsidiaries have already adopted the new name, and the stock will continue trading under the symbol 'LFWD' on Nasdaq. The new name will be effective for trading starting September 13, 2024.
Lifeward (Nasdaq: LFWD) has appointed Dr. Keith E. Tansey as Consulting Director of Clinical Research. With over 30 years of experience in spinal cord injury research and treatment, Dr. Tansey brings valuable expertise to Lifeward's Medical Affairs team. His responsibilities include developing the company's clinical research program, advancing key opinion leader opportunities, and supporting clinical partnerships to expand the use of personal exoskeletons for individuals with spinal cord injuries.
Dr. Tansey, a Professor at the University of Mississippi Medical Center and a Physician Scientist at the Veterans Administration Medical Center, is board-certified in Neurology with subspecialty certifications in Spinal Cord Injury Medicine and Neural Repair and Rehabilitation. His appointment aligns with Lifeward's mission to improve the lives of individuals with physical limitations or disabilities through innovative rehabilitation solutions.
Lifeward (Nasdaq: LFWD) has successfully completed its first ReWalk Step Challenge 2024, a charity initiative involving ReWalk Personal Exoskeleton users in Germany. The challenge resulted in a €5,000 donation to the Association for the Promotion of Paraplegics in Germany (FGQ). Participants collectively achieved 424,844 steps during the one-month challenge, with Lifeward donating one cent per step taken.
The funds will support FGQ's mission to assist people with spinal cord injuries and their families. Lifeward CEO Larry Jasinski expressed satisfaction with the community's engagement and the opportunity to support the European Spinal Cord Injury Federation (ESCIF). The company plans to repeat the challenge next year, aiming for increased participation to further support the paraplegic community.
Lifeward (Nasdaq: LFWD), a global leader in rehabilitation and recovery solutions, will participate in the H.C. Wainwright 26th Annual Global Investment Conference from September 9-11, 2024 in New York City. CEO Larry Jasinski will present and meet with investors, with a recorded webcast available from 1:30 pm EDT on September 11, 2024.
The presentation offers Lifeward an opportunity to showcase its innovative products, including the ReWalk Exoskeleton, AlterG Anti-Gravity system, MyoCycle FES bike, and ReStore Exo-Suit. These solutions aim to improve the standard of care for individuals with physical limitations or disabilities, providing functional and health benefits in clinical, home, and community settings.
Lifeward (LFWD) reported record Q2 2024 revenue of $6.7M, up over 400% from $1.3M in Q2 2023. Key highlights include:
1. ReWalk revenue growth with 20 systems placed
2. Medicare claims for prior quarters beginning to be paid
3. Successful launch of NEO product line with Differential Air Pressure Anti-Gravity Technology
4. FDA submission for 7th generation ReWalk design
Financial results:
- Gross margin: 41.1% (46.9% non-GAAP)
- Operating loss: $4.4M ($3.7M non-GAAP)
- Net loss: $4.3M or $0.50 per share ($3.6M or $0.42 per share non-GAAP)
- Cash position: $15.1M with no debt
Lifeward maintains its 2024 revenue guidance of $28M to $32M, expecting sequential quarterly improvement.
Lifeward (Nasdaq: LFWD), formerly known as ReWalk Robotics, has announced it will release its second quarter 2024 financial results on August 15, 2024, before the markets open. The company, which specializes in rehabilitation and recovery solutions, will host a conference call and live webcast at 8:30 a.m. EDT on the same day. CEO Larry Jasinski and CFO Michael Lawless will lead the discussion of the financial results.
Investors and analysts can access the call through various toll-free and international numbers. The webcast will be available through the company's website at GoLifeward.com in the 'Investors' section and will also be archived for future viewing.
Lifeward has announced the retirement of Jeff Dykan, its Chairman of the Board, effective at the 2024 Annual Meeting of Shareholders. Dykan, who has led the company for 15 years, will be succeeded by Joseph Turk, a board member since 2022. Under Dykan's leadership, Lifeward, formerly known as ReWalk Robotics, achieved several milestones including FDA De Novo approval, an IPO, VA exoskeleton policy, and Medicare reimbursement for personal exoskeletons. Turk aims to leverage this foundation to drive commercial expansion and market development for Lifeward's ReWalk and AlterG product lines.
Lifeward has launched the AlterG NEO Anti-Gravity Treadmill, featuring an updated, user-friendly design and Leveraging Differential Air Pressure (DAP) technology. This treadmill aims to offer precise and consistent unweighting for physical rehabilitation and athletic training at a cost-effective price. The new model is expected to broaden access to this advanced technology for more clinics and training facilities. CEO Larry Jasinski highlighted that the NEO is a testament to Lifeward's commitment to expanding their market reach and helping more patients benefit from Anti-Gravity rehabilitation. The AlterG NEO will debut at the National Athletic Trainers Association (NATA) Clinical Symposia & AT Expo on June 26-27, 2024, in New Orleans.
FAQ
What is the current stock price of Lifeward Ltd. Ordinary Shares (LFWD)?
What is the market cap of Lifeward Ltd. Ordinary Shares (LFWD)?
What is Lifeward?
What products does Lifeward offer?
Where does Lifeward operate?
What recent achievements has Lifeward made?
How does the ReWalk Personal Exoskeleton benefit users?
What is the CMS reimbursement pathway for the ReWalk Personal Exoskeleton?
Who founded Lifeward and when?
What is Lifeward's mission?
How can I learn more about Lifeward's products and mission?
Who should I contact for media or investor relations at Lifeward?
